Medical Cannabis Not Recommended for Sleep Apnea

Share this content:
Medical Cannabis Not Recommended for Sleep Apnea
Medical Cannabis Not Recommended for Sleep Apnea

FRIDAY, April 20, 2018 (HealthDay News) -- Medical cannabis and/or its synthetic extracts should not be used for treating patients with obstructive sleep apnea (OSA), according to an American Academy of Sleep Medicine position statement published in the April 15 issue of the Journal of Clinical Sleep Medicine.

Noting that limited evidence suggests that the synthetic medical cannabis extract dronabinol may be beneficial in OSA, Kannan Ramar, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues explored its use.

The researchers write that side effects associated with dronabinol treatment, including somnolence, were reported in most patients, while long-term effects on sleep quality measures, safety, and tolerability are unknown. Dronabinol has not been approved by the U.S. Food and Drug Administration as a treatment for OSA; medical cannabis and other synthetic extracts have not been assessed for OSA. Within medical cannabis, the composition of cannabinoids varies significantly, with no regulation. Due to unreliable delivery methods and insufficient evidence on effectiveness, tolerability, and safety, the American Academy of Sleep Medicine concludes that medical cannabis and/or its synthetic extracts should not be used for OSA treatment.

"OSA should be excluded from the list of chronic medical conditions for state medical cannabis programs, and patients with OSA should discuss their treatment options with a licensed medical provider at an accredited sleep facility," the authors write. "Further research is needed to understand the functionality of medical cannabis extracts before recommending them as a treatment for OSA."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »